FDA Grants Priority Review to Huntington Disease Gene Therapy BLA

03 Nov 2026 0 comments

The FDA accepted uniQure's biologics license application for ifezuntirgene inilparvovec and granted it Priority Review, setting a target action date of May 1, 2027.

Source: NeurologyLive Published 02 Nov 2026 Imported 02 Nov 2026 Relevancy: Not reviewed

Read the article

Comments

No comments yet.

Unrestricted

All comments are reviewed before being published. Most comments are approved unless they are clearly inappropriate or unsafe.

Comments

Leave a comment